Does the media favor AUTL or XERS?

In the previous week, Autolus Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Xeris Biopharma. Autolus Therapeutics' average media sentiment score of 0.85 beat Xeris Biopharma's score of 0.77 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SEPN or AUTL?

In the previous week, Autolus Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Autolus Therapeutics' score of 0.85 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNNN or AUTL?

Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 380.77%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Which has better earnings & valuation, NNNN or AUTL?

Anbio Biotechnology has higher earnings, but lower revenue than Autolus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 177.23 $6.40M N/A N/A Autolus Therapeutics $92.62M 5.23 -$287.53M -$1.09 N/A

Does the media refer more to NNNN or AUTL?

In the previous week, Autolus Therapeutics had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Autolus Therapeutics and 1 mentions for Anbio Biotechnology. Autolus Therapeutics' average media sentiment score of 0.85 beat Anbio Biotechnology's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or PAHC?

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 7 articles in the media. Autolus Therapeutics' average media sentiment score of 0.85 beat Phibro Animal Health's score of 0.69 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Autolus Therapeutics (AUTL) Competitors

$1.82 +0.33 (+22.15%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 04:23 PM Eastern

Compare

AUTL vs. XERS, SEPN, MLTX, NNNN, and PAHC

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Xeris Biopharma (XERS), Septerna (SEPN), MoonLake Immunotherapeutics (MLTX), Anbio Biotechnology (NNNN), and Phibro Animal Health (PAHC).

How does Autolus Therapeutics compare to Xeris Biopharma?

Autolus Therapeutics (NASDAQ:AUTL) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Autolus Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Xeris Biopharma. Autolus Therapeutics' average media sentiment score of 0.85 beat Xeris Biopharma's score of 0.77 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Autolus Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 380.77%. Xeris Biopharma has a consensus target price of $10.80, suggesting a potential upside of 32.84%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Xeris Biopharma has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50

Xeris Biopharma has a net margin of 3.81% compared to Autolus Therapeutics' net margin of -311.98%. Xeris Biopharma's return on equity of 735.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Xeris Biopharma	3.81%	735.00%	3.24%

Summary

Autolus Therapeutics beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Septerna has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Septerna presently has a consensus price target of $45.89, suggesting a potential upside of 31.19%. Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 380.77%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Septerna has a net margin of -49.88% compared to Autolus Therapeutics' net margin of -311.98%. Septerna's return on equity of -12.72% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

72.8% of Autolus Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Autolus Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Autolus Therapeutics' score of 0.85 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has higher earnings, but lower revenue than Autolus Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$72.26M	21.82	-$48.88M	-$0.81	N/A
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A

Summary

Septerna beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to MoonLake Immunotherapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. MoonLake Immunotherapeutics' return on equity of -85.15% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

In the previous week, MoonLake Immunotherapeutics had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 13 mentions for MoonLake Immunotherapeutics and 7 mentions for Autolus Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Autolus Therapeutics' score of 0.85 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 380.77%. MoonLake Immunotherapeutics has a consensus price target of $24.21, suggesting a potential upside of 39.16%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Autolus Therapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Autolus Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Autolus Therapeutics beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Anbio Biotechnology has higher earnings, but lower revenue than Autolus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	177.23	$6.40M	N/A	N/A
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A

Anbio Biotechnology has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Anbio Biotechnology's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

In the previous week, Autolus Therapeutics had 6 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Autolus Therapeutics and 1 mentions for Anbio Biotechnology. Autolus Therapeutics' average media sentiment score of 0.85 beat Anbio Biotechnology's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 380.77%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anbio Biotechnology has a beta of 5.15, meaning that its stock price is 415% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Summary

Autolus Therapeutics beats Anbio Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Phibro Animal Health?

Autolus Therapeutics (NASDAQ:AUTL) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Autolus Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Phibro Animal Health has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
Phibro Animal Health	$1.30B	1.16	$48.26M	$2.33	15.94

Autolus Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 380.77%. Phibro Animal Health has a consensus target price of $42.50, indicating a potential upside of 14.40%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Autolus Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has a net margin of 6.35% compared to Autolus Therapeutics' net margin of -311.98%. Phibro Animal Health's return on equity of 37.14% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Phibro Animal Health	6.35%	37.14%	8.57%

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 7 articles in the media. Autolus Therapeutics' average media sentiment score of 0.85 beat Phibro Animal Health's score of 0.69 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phibro Animal Health beats Autolus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$484.40M	$3.51B	$6.81B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-1.67	7.34	281.03	25.13
Price / Sales	5.23	1,215.58	574.87	80.86
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.72	16.89	11.03	6.21
Net Income	-$287.53M	-$12.54M	$3.48B	$347.60M
7 Day Performance	24.66%	-0.63%	0.54%	0.88%
1 Month Performance	15.19%	-7.39%	-4.19%	-3.62%
1 Year Performance	-22.55%	49.17%	63.11%	20.46%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	2.5048 of 5 stars	$1.82 +22.1%	$8.75 +380.8%	-36.6%	$484.40M	$92.62M	N/A	330	News Coverage Analyst Downgrade Gap Up High Trading Volume
XERS Xeris Biopharma	3.8043 of 5 stars	$8.60 -2.3%	$10.80 +25.6%	+50.2%	$1.52B	$291.85M	143.33	290	News Coverage Positive News Upcoming Earnings
SEPN Septerna	2.6804 of 5 stars	$32.21 -3.6%	$45.89 +42.5%	+182.1%	$1.51B	$45.95M	N/A	N/A	Positive News Upcoming Earnings
MLTX MoonLake Immunotherapeutics	3.7427 of 5 stars	$19.05 -3.2%	$24.21 +27.1%	-65.2%	$1.45B	N/A	N/A	2	Upcoming Earnings
NNNN Anbio Biotechnology	0.4335 of 5 stars	$9.52 +0.3%	N/A	N/A	$1.37B	$8.65M	N/A	27	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. XERS, SEPN, MLTX, NNNN, and PAHC

How does Autolus Therapeutics compare to Xeris Biopharma?

Summary

How does Autolus Therapeutics compare to Septerna?

Summary

How does Autolus Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Autolus Therapeutics compare to Anbio Biotechnology?

Summary

How does Autolus Therapeutics compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. XERS, SEPN, MLTX, NNNN, and PAHC

How does Autolus Therapeutics compare to Xeris Biopharma?

Do insiders & institutionals hold more shares of AUTL or XERS?

Does the media favor AUTL or XERS?

Which has more risk & volatility, AUTL or XERS?

Do analysts rate AUTL or XERS?

Which has stronger valuation & earnings, AUTL or XERS?

Is AUTL or XERS more profitable?

Summary

How does Autolus Therapeutics compare to Septerna?

Which has more risk and volatility, SEPN or AUTL?

Do analysts rate SEPN or AUTL?

Is SEPN or AUTL more profitable?

Do insiders and institutionals have more ownership in SEPN or AUTL?

Does the media prefer SEPN or AUTL?

Which has stronger earnings and valuation, SEPN or AUTL?

Summary

How does Autolus Therapeutics compare to MoonLake Immunotherapeutics?

Is AUTL or MLTX more profitable?

Does the media prefer AUTL or MLTX?

Do analysts rate AUTL or MLTX?

Which has higher earnings & valuation, AUTL or MLTX?

Do institutionals and insiders have more ownership in AUTL or MLTX?

Which has more volatility & risk, AUTL or MLTX?

Summary

How does Autolus Therapeutics compare to Anbio Biotechnology?

Which has better earnings & valuation, NNNN or AUTL?

Is NNNN or AUTL more profitable?

Does the media refer more to NNNN or AUTL?

Do analysts rate NNNN or AUTL?

Do institutionals & insiders have more ownership in NNNN or AUTL?

Which has more risk and volatility, NNNN or AUTL?

Summary

How does Autolus Therapeutics compare to Phibro Animal Health?

Which has more risk and volatility, AUTL or PAHC?

Do institutionals and insiders believe in AUTL or PAHC?

Which has stronger earnings and valuation, AUTL or PAHC?

Do analysts prefer AUTL or PAHC?

Is AUTL or PAHC more profitable?

Does the media prefer AUTL or PAHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools